Maze Therapeutics, Inc. - 10-Q Filing

Maze Therapeutics reports Q3 2026 results featuring Hercules Term Loan Facility obligations and various license agreement milestones.

SEC EDGAR ·

Tickers: $MAZE

Read the full article at SEC EDGAR

More Regulatory news